|Day's range||12.44 - 28.50|
Viking (VKTX) announces positive clinical data, evaluating VK2735 to treat metabolic disorders. It is also initiating an early-stage extension study on the same.
Viking could have a strong rival to Novo Nordisk's Wegovy and Ozempic and Lilly's Mounjaro in the making.
In the latest trading session, Novo Nordisk (NVO) closed at $155.32, marking a +0.4% move from the previous day.